CAT-VHL - Exploring the role of Carbonic Anhydrase IX as diagnostic and Theranostic target in Von-Hippel Lindau disease

2024-515679-36-01 · tracked via the Priya Life Science EU tracker

Sponsor

Ospedale San Raffaele S.r.l.

Sponsor type

Hospital/Clinic/Other health care facility

Therapeutic area

Therapeutics

Decision date

24/10/2025

Enrollment target

Sites

Italy

Condition studied

Von-Hippel Lindau (VHL) Disease

Investigational medicinal product(s)

Zr-DFO-girentuximab

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Primary endpoint

To evaluate the efficacy of CAIX-PET for the detection of tumors in patients with VHL disease.

Endpoint detail

To evaluate the diagnostic accuracy of CAIX-PET in VHL -/- tumors diagnosed in the sporadic setting., To evaluate the diagnostic accuracy of CAIX-PET in VHL disease., To evaluate the safety of CAIX-PET.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-515679-36-01 on CTIS ↗ ← All trials in the EU